Corporate Member Update: Boehringer Ingelheim, Inc.-G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib)
Corporate Member Update: Boehringer Ingelheim, Inc.-G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib)
COSELA™ (trilaciclib)
March, 2021
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib)
A new product was just approved by the FDA, and Boehringer Ingelheim is in a Co-Promotion with G1 Therapeutics. For more information please see the press release here and visit www.COSELA.com.
